🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

BeiGene (BGNE)

NASDAQ
Currency in USD
208.03
+0.78(+0.38%)
Closed
After Hours
208.030.00(0.00%)
BGNE Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Earnings results expected in 6 days
Fair Value
Day's Range
205.63209.99
52 wk Range
126.97248.16
Prev. Close
208.03
Open
208.13
Day's Range
205.63-209.99
52 wk Range
126.97-248.16
Volume
322,583
Average Volume (3m)
328,969
1-Year Change
6.06%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
BGNE Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
276.99
Upside
+33.15%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

BeiGene ADS Company Profile

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Compare BGNE to Peers and Sector

Metrics to compare
BGNE
Peers
Sector
Relationship
P/E Ratio
−42.2x−6.7x−0.6x
PEG Ratio
−0.60−0.020.00
Price/Book
6.6x3.9x2.6x
Price / LTM Sales
7.1x8.1x3.2x
Upside (Analyst Target)
38.2%29.3%46.3%
Fair Value Upside
Unlock28.2%6.1%Unlock

People Also Watch

30.92
ZLAB
+0.10%
5.44
IBRX
+4.62%
227.44
STE
+0.72%
20.57
ARWR
+2.54%
2.1600
SGMO
+24.14%

FAQ

What Is the BeiGene ADS (BGNE) Stock Price Today?

The BeiGene ADS stock price today is 208.03

What Stock Exchange Does BeiGene ADS Trade On?

BeiGene ADS is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for BeiGene ADS?

The stock symbol for BeiGene ADS is "BGNE."

What Is the BeiGene ADS Market Cap?

As of today, BeiGene ADS market cap is 22.10B.

What is BeiGene ADS Earnings Per Share?

The BeiGene ADS EPS is -5.01.

What Is the Next BeiGene ADS Earnings Date?

BeiGene ADS will release its next earnings report on 12 Nov 2024.

From a Technical Analysis Perspective, Is BGNE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.